uniQure (NASDAQ:QURE) Stock Price Down 7.8% – Should You Sell?

uniQure N.V. (NASDAQ:QURE) was down 7.8% during mid-day trading on Thursday . The stock traded as low as $26.83 and last traded at $26.8950. Approximately 905,115 shares were traded during mid-day trading, a decline of 68% from the average daily volume of 2,857,977 shares. The stock had previously closed at $29.17.

Wall Street Analysts Forecast Growth

A number of research firms have commented on QURE. Royal Bank Of Canada upgraded uniQure from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $11.00 to $35.00 in a research report on Monday, March 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, January 21st. Chardan Capital lifted their price target on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Barclays cut their price target on uniQure from $31.00 to $25.00 and set an “equal weight” rating for the company in a research note on Monday, March 23rd. Finally, Stifel Nicolaus set a $28.00 target price on shares of uniQure in a research note on Tuesday, May 5th. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $42.83.

uniQure Stock Down 5.0%

The stock has a 50 day moving average of $17.58 and a 200-day moving average of $23.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The firm has a market capitalization of $1.75 billion, a P/E ratio of -7.96 and a beta of 0.87.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. Research analysts predict that uniQure N.V. will post -3.68 earnings per share for the current fiscal year.

Insider Buying and Selling

In other uniQure news, insider Jeannette Potts sold 3,412 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $30,912.72. Following the sale, the insider directly owned 138,483 shares in the company, valued at $1,254,655.98. This represents a 2.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Matthew C. Kapusta sold 14,581 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $132,103.86. Following the completion of the transaction, the chief executive officer directly owned 660,658 shares of the company’s stock, valued at approximately $5,985,561.48. The trade was a 2.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 94,396 shares of company stock valued at $1,850,434. Corporate insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of QURE. Torren Management LLC purchased a new position in uniQure in the 4th quarter worth approximately $28,000. Jones Financial Companies Lllp increased its holdings in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the period. IFP Advisors Inc bought a new stake in uniQure in the fourth quarter valued at approximately $48,000. Smartleaf Asset Management LLC bought a new stake in uniQure during the 4th quarter valued at $48,000. Finally, CIBC Private Wealth Group LLC purchased a new stake in shares of uniQure during the third quarter worth about $50,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.